Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667409 | 0.91 | PPARA (0.59) | LMNAKMT2APPARAPPARGTHRA | |
| SCHEMBL15199294 | 0.89 | PPARA (0.64) | LMNAKMT2APPARAPPARGTHRA | |
| SCHEMBL4898454 | 0.88 | LMNA (0.61) | LMNAKMT2APPARAPPARGPKM | |
| SCHEMBL31279691 | 0.82 | MAOB (0.69) | KMT2A | |
| SCHEMBL11463053 | 0.81 | ERCC5 (0.63) | LMNAKMT2ATHRATHRBHTT | |
| SCHEMBL4060556 | 0.81 | MAOB (0.67) | LMNAKMT2APKMHTTMAPK1 | |
| SCHEMBL29953637 | 0.81 | MAOB (0.67) | LMNAKMT2APKMHTTMAPK1 | |
| SCHEMBL3811204 | 0.81 | L3MBTL1 (0.58) | PLA2G4BALOX15HPGD | |
| SCHEMBL4637827 | 0.81 | CES2 (0.62) | KMT2AHPGD | |
| SCHEMBL10167730 | 0.80 | NR4A2 (0.65) | LMNAKMT2APKMHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
| EP-1951216-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062145-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | LMNA 4607/4885KMT2A 1969/4885PPARA 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.